← Leaderboards
Marina Gorbatyuk
University Of North Texas Hlth Sci Ctr
$5,759,770
Attributed
$6,191,022
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,191,022 · 5
By mechanism
R01$5,894,022 · 4
R21$297,000 · 1
Top collaborators
- Maria B Grant2 shared
- Qingguo Xu2 shared
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularRetinaPathogenesisBlindnessMediatingAnimal ModelAffectResponseSignal TransductionProteinsPhotoreceptorsCell DeathBaseMouse ModelChronicRetinal DegenerationGenesPathway InteractionsPublishingEndoplasmic Reticulum StressPathologicEndoplasmic ReticulumBiological Adaptation To StressInherited
Grant awards (21)
RXR-based therapy for diabetic retinopathy$559,365
R01 · FY2025 · EY · contact PI
RXR-based therapy for diabetic retinopathy$500,473
R01 · FY2024 · EY · contact PI
The mechanism of vesicant-induced ocular injury$426,367
R01 · FY2024 · EY · contact PI
Postnatal Mice as a Pediatric Research Model for Investigating Direct Ocular Exposure to Vesicants$146,855
R01 · FY2024 · EY · contact PI
RXR-based therapy for diabetic retinopathy$87,513
R01 · FY2024 · EY · contact PI
The mechanism of vesicant-induced ocular injury$19,134
R01 · FY2024 · EY · contact PI
The mechanism of vesicant-induced ocular injury$445,500
R01 · FY2023 · EY · contact PI
The mechanism of vesicant-induced ocular injury$445,500
R01 · FY2022 · EY · contact PI
Molecular mechanisms of translational control in mice with inherited retinal degeneration$360,113
R01 · FY2022 · EY · contact PI
Molecular mechanisms of translational control in mice with inherited retinal degeneration$360,112
R01 · FY2021 · EY · contact PI
Molecular mechanisms of translational control in mice with inherited retinal degeneration$371,250
R01 · FY2020 · EY · contact PI
Post-translational histone modification in ocular tissues of mice exposed to arsenicals$124,520
R01 · FY2020 · EY · contact PI
Molecular mechanisms of translational control in mice with inherited retinal degeneration$371,250
R01 · FY2019 · EY · contact PI
Development and Validation of a Tree Shrew Model of Diabetic Retinopathy$297,000
R21 · FY2019 · EY · contact PI
Molecular mechanisms of translational control in mice with inherited retinal degeneration$371,250
R01 · FY2018 · EY · contact PI
Unfolded Protein Response as a Therapeutic Target for ADRP Animal Models$271,138
R01 · FY2014 · EY · contact PI
Unfolded Protein Response as a Therapeutic Target for ADRP Animal Models$262,838
R01 · FY2013 · EY · contact PI
Unfolded Protein Response as a Therapeutic Target for ADRP Animal Models$241,327
R01 · FY2012 · EY · contact PI
Unfolded Protein Response as a Therapeutic Target for ADRP Animal Models$35,345
R01 · FY2012 · EY · contact PI
Unfolded Protein Response as a Therapeutic Target for ADRP Animal Models$276,672
R01 · FY2011 · EY · contact PI
Unfolded Protein Response as a Therapeutic Target for ADRP Animal Models$217,500
R01 · FY2010 · EY · contact PI